article thumbnail

4th Gene Therapy Analytical Development Summit 2022

pharmaphorum

As the field strives to strike a delicate balance between safety and efficacy, in the context of increased regulatory scrutiny and safety challenges, attending the 4 th Annual Gene Therapy Analytical Development as an analytical scientist has never been so important. Download the full event guide to find out more.

article thumbnail

Using analytics and bioassays to de-risk your mRNA LNP drug development programme

Pharmaceutical Technology

The swift development and deployment of messenger-RNA (mRNA) vaccines against the SARS-CoV-2 virus during the COVID-19 crisis has catapulted the pharmaceuticals industry into a new paradigm. Another area where we tend to see problems is in encapsulation efficiency,” says Andrew Kondratowicz, Bioassay Team Lead, Precision NanoSystems.

Bioassay 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Reimagining cell engineering with picodroplet microfluidic technology

Drug Discovery World

Cell engineering is bringing life science into a new era of biotherapeutic discovery and development, disease modelling, and synthetic biology research. Furthermore, evidence of monoclonality must be provided for all cell lines producing biotherapeutic molecules if they are to receive approval from industry regulators.

article thumbnail

RNA-based immunotherapy eradicates melanoma tumours

Drug Discovery World

This is because tumours have a tendency to evolve in different ways to switch off each stage of the cancer-immunity cycle,” said Yizhou Dong, corresponding author of the study, Professor of Oncological Sciences, and a member of the Icahn Genomics Institute and the Marc and Jennifer Lipschultz Precision Immunology Institute at Icahn Mount Sinai.

RNA 52
article thumbnail

Evaluating methods targeting Protein-Protein Interactions

pharmaphorum

The issue, however, is developing an effective way of targeting them. . Understanding the mechanism of PPIs and developing methods to target aberrant ones has been a key strategy in drug development. The flat interface remains the primary challenge facing the development of PPI modulators.

Protein 126
article thumbnail

Can artificial intelligence help craft new medicines?

Drug Discovery World

The potential of drug targets Over the next 50 years, new targets emerged and drugs were developed against them. Here, new bioassay technologies helped testing, but more definite answers were required. Often drug targets already validated in academic literature are picked up for drug discovery and development efforts.